The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys
- Authors: Milovanov Y.S.1, Kozlovskaya L.V.1, Milovanova L.Y.1, Milovanov Y.S2, Kozlovskaya LV2, Milovanova LY.2
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 83, No 6 (2011)
- Pages: 70-73
- Section: Editorial
- Submitted: 10.04.2020
- Published: 15.06.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30888
- ID: 30888
Cite item
Full Text
Abstract
Keywords
About the authors
Yuriy Sergeevich Milovanov
Email: yumil2010@rambler.ru
Lidiya Vladimirovna Kozlovskaya
Email: lkoslovckay@mail.ru
Lyudmila Yur'evna Milovanova
Email: lussya2000@mail.ru
Yu S Milovanov
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
L V Kozlovskaya
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
L Yu Milovanova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
References
- Agarwal R., Acharya M., Tian J. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 (6): 2823-2828.
- Coyne D., Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 2006; 47 (2): 263-276.
- Krajisnik T., Bjorklund P., Marsel R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1-alfa-hydroxylaseexpression in cultured bovine parathyroid cells. J. Endocrinol. 2007; 195: 125-131.
- Sprague S. M., Liach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 64 (4): 1483-1490.
- Lindberg J., Martin K. J. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56 (4): 315-323.
- Teng M., Wolf M., Lowrie E. et al. Survival of patients undergoing hemodialysis with paricacitol or calcitriol therapy. N. Engl. J. Med. 2003; 349 (5): 446-456.
- Martin K. J., Gonzalez M. G. et al. 19-Nor-1-a-25 Dihydroxyvitamin D2 (Paricalcitol) safety and affectively reduces the levels of the intact Parathyroid Hormone in patients on Hemodialysis. J. Am. Soc. Nephrol. 1998; 9: 1427-1432.
- Liach F., Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 2001; 38 (Suppl. 5): S45-S50.
- Schumock G. T. Comparative effectiveness of aricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin. Pract. 2010; 117 (2): 151-159.
- Dobrez D. G., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitrioltreated patients in real-world clinical settings. Nephrol. Dial. Transplant. 2004; 19: 1174-1181.
- Schumack G. T., Arruda J. A. L., Marx S. E. et. al. Economic comparison of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism impact of hospitalization and survival. J. Med. Econ. 2007; 10: 393-409.
Supplementary files
![](/img/style/loading.gif)